During the last few years, we have put a concerted effort in characterising the metabolic and lipoprotein profile of prostate, pancreatic and liver cancer in with some African cohorts. In pancreatic and liver cancer, we identified a metabolite marker strongly associated with the survival time. We believe that this marker is associated with a high oxidative stress in the liver and consequently could have a strong impact in the immune system.
We aim to compare our results obtained in African patients with the data from the UK Biobank.
The impact of this study will directly benefit cancer patients since it may lead to the identification of non-invasive early prognostic biomarkers and the identification of metabolic pathways that can be targeted to counteract disease progression and therapeutic efficacy.
